- Report
- November 2025
- 199 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- November 2025
- 192 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- November 2025
- 150 Pages
Global
From €5211EUR$5,950USD£4,523GBP
- Report
- October 2025
- 150 Pages
Global
From €5211EUR$5,950USD£4,523GBP
- Report
- September 2025
- 130 Pages
Global
From €5211EUR$5,950USD£4,523GBP
- Report
- March 2025
- 120 Pages
Global
From €5211EUR$5,950USD£4,523GBP
- Report
- February 2025
- 180 Pages
Global
From €5211EUR$5,950USD£4,523GBP
- Report
- January 2026
- 307 Pages
Global
From €3941EUR$4,500USD£3,421GBP
- Report
- March 2025
- 120 Pages
Global
From €4292EUR$4,900USD£3,725GBP
- Report
- November 2025
- 189 Pages
Global
From €4292EUR$4,900USD£3,725GBP
- Report
- February 2026
- 307 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- January 2026
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- January 2026
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- December 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- December 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- December 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- February 2026
- 224 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 235 Pages
Global
From €5124EUR$5,850USD£4,447GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more